Can Pharma Ignore Turing’s Price Hikes?

Posted by Ed Schoonveld on Tue, Sep 22, 2015

Turing Pharmaceuticals caused uproar in political and medical communities with its price increase from $13.50 to $750 per pill in August for Daraprim, a toxoplasmosis treatment that was developed in 1953. It has added fuel to the already hot debate over prescription drug pricing. Turing’s CEO Martin Shkreli called the move a “smart business decision”, hardly a formulation that eases criticism in an environment where healthcare funding decisions are increasingly emotional and tough. “Price gouging” and “unscrupulous” are some of the terms used in reactions that have been dominating the news over the last few days.


>
Read More

Oncology Drug Pricing After ASCO Value Framework and DrugAbacus

Posted by Ed Schoonveld on Tue, Jul 21, 2015

The U.S. medical community has been increasingly vocal over the high cost of oncology drugs and its impact on the ability to treat patients. Oncologists coined the term “financial toxicity” to indicate the need to consider patient cost as a component in treatment decision making.


>
Read More

Is Express Scripts the New Robin Hood?

Posted by Ed Schoonveld on Fri, Jan 30, 2015

Express Scripts (ESI) has been drawing a lot of publicity recently over its strong stance on drug pricing and willingness to engage in exclusive formulary listing agreements for high-cost specialty drugs. Particularly with respect to hepatitis C drugs, ESI initiated an exclusive contract with AbbVie’s Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets,) which came second to market after Gilead’s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir and ledipasvir).


>
Read More

Top Three Issues in Market Access?

Posted by Ed Schoonveld on Wed, Jan 28, 2015

The prescription drug industry is under a lot of change with the Affordable Care Act, heavy drug pricing debates for oncology and hepatitis C, and many system reforms in Europe.


>
Read More

Pricing Controversy Flares in 2014 After Sovaldi Launch

Posted by Ed Schoonveld on Tue, Dec 23, 2014

A recent interview I did with Investor’s Business Daily covered many hot drug-pricing topics. The launch of Sovaldi, angry reactions from PBM Express scripts and concerned physicians and patients have provoked a lot of dialogue globally on drug pricing and affordability.


>
Read More